Nearly 1 in 10 individuals develop an allergy to betalactams, the most common class of antibiotics. The current method of diagnosing betalactam allergy is the conventional skin test which, however, may have adverse effects. The scope of the EU-funded ASSERT project is to advance the basophil activation test (BAT) as a routine diagnostic method for betalactam allergy. BAT measures activation of basophils that mediate allergic reactions by releasing histamine following stimulation with allergen. Researchers will employ nanotechnology to improve the precision and reproducibility of the BAT assay and validate it for routine clinical use.